A phase II study of Atezolizumab for advanced / recurrent Non-Small Cell Lung Cancer with Idiopathic Interstitial Pneumonias
Latest Information Update: 20 Sep 2022
At a glance
- Drugs Atezolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms AMBITIOUS
- 02 Sep 2022 Results published in the Oncologist
- 21 Sep 2021 Results presented at the 46th European Society for Medical Oncology Congress
- 02 Sep 2020 New trial record